Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q96DX5
UPID:
ASB9_HUMAN
Alternative names:
-
Alternative UPACC:
Q96DX5; A8K8A5; Q9BVF5; Q9NWS5; Q9Y4T3
Background:
Ankyrin repeat and SOCS box protein 9 plays a crucial role in cellular processes as part of the SCF-like ECS E3 ubiquitin-protein ligase complex. It specifically targets creatine kinase forms, CKB and CKMT1A, for ubiquitination and proteasomal degradation, maintaining cellular protein homeostasis.
Therapeutic significance:
Understanding the role of Ankyrin repeat and SOCS box protein 9 could open doors to potential therapeutic strategies.